References

  1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology. 2007 Feb; 6(2):182-7. PubMed | Google Scholar

  2. Feigin VL, Lawes CM, Bennett DA et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurology. 2009 Apr; 8(4):355-69. PubMed | Google Scholar

  3. Engels T, Baglione Q, Audibert M, Viallefont A, Mourji F, El Alaoui Faris M. GRAVCM Study Group Socioeconomic status and stroke prevalence in Morocco: results from the Rabat-Casablanca study. PLoS One. 2014 Feb 28; 9(2):e89271. PubMed | Google Scholar

  4. Ghandehari K. Barriers of Thrombolysis therapy in developing Countries. Stroke Research and Treatment. 2011; Volume 2011 (Article ID 686797): 4 pages. PubMed | Google Scholar

  5. Belkouch A, Jidane S, Chouaib N, Elbouti A, Nebhani T, Sirbou R, Bakkali H, Belyamani L. Thrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital. The Pan African Medical Journal. 2015; 21:37. PubMed | Google Scholar

  6. Adams Jr HP and al. Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke A Statement for Healthcare Professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996 Sep 1; 94(5):1167-74. PubMed | Google Scholar

  7. Barber PA, Demchuk AM, Zhang J, Buchan AM. For the ASPECTS Study Group: validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy; Alberta Stroke Program Early CT Score. Lancet. 2000 May; 355 (9216):1670-74. PubMed | Google Scholar

  8. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009 Dec;8(12):1095-102. PubMed | Google Scholar

  9. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27; 369(9558):275-82. PubMed | Google Scholar

  10. Niaz A, Lars K, Kennedy RL, Robert M, Turgut T, Danilo T. For the SITS Investigators Results of Intravenous Thrombolysis Within 4.5 to 6 Hours and Updated Results Within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): An observational study. JAMA Neurology. 2013 Jul;70(7):837-44. PubMed | Google Scholar

  11. National Institute of Neurological Disorders and Stroke rt-PA StrokeStudy Group. Tissue plasminogen activator for acute ischemic stroke. NEngl J Med.1995; 333: 1581-87. PubMed | Google Scholar

  12. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003 Dec; 34 (12):2847-50. PubMed | Google Scholar

  13. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early strok treatment: pooled analysis of ATLANTIS , ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363:768-774. PubMed | Google Scholar

  14. Wardlaw JM, Murray V, Berge E et al. Thromobolysis for acute ischemic stroke. Cochrane Database Syst Rev. 2009 Oct 7;4: CD000213. PubMed | Google Scholar